Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Regular human insulin · Afrezza

Recombinant protein · Agonist of insulin receptor (INSR) · developed by Mannkind

Approved FDA, Jun 2014
MNKD Developer
1 Registered trials

What is Regular human insulin?

Regular human insulin is a recombinant human insulin that lowers blood glucose by stimulating glucose uptake in skeletal muscle and fat and by inhibiting hepatic glucose production. It also inhibits lipolysis and proteolysis and enhances protein synthesis. It is used to improve glycemic control in diabetes mellitus.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Afrezza
Drug type
Recombinant protein
Targets
insulin receptor (INSR)
Mechanism
Agonist of insulin receptor (INSR)
Pathways
glucose uptake by skeletal muscle and fat, inhibition of hepatic glucose production, inhibition of lipolysis, enhancement of protein synthesis
Therapy area
Endocrine, Metabolic
Developer
Mannkind (MNKD)
FDA status
Approved as Afrezza (June 27, 2014), BLA022472 · FDA label

✅ FDA-approved uses

From the indications section of the FDA label (version of May 30, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT01490762 Phase 1 Healthy Completed MNKD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Healthy

Other drugs acting on INSR

More from Mannkind

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the MNKD page.

Follow MNKD, the company behind Regular human insulin

See MNKD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MNKD catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.